The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1
Open accessAbstract
The purpose of this study was to determine the response to CPT-11 administered every three weeks to adults with progressive malignant glioma, treated with or without enzyme-inducing antiepileptic drug (EIAED) therapy, at the recommended phase 2 dose determined from a previous phase 1 study. Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible. No more than one prior chemotherapy was allowed, either as adjuvant therapy or for recurrent disease. The CPT-11 dose was 350 mg/m(2) i.v. every three weeks in patients not on EIAED and 750 mg/m(2) in patients on EIAED therapy. Patients with stable or responding disease could be treated until tumor progression or a total of 12 months of therapy. The primary end point of the study was to determine whether CPT-11 could significantly delay tumor progression, using the rate of six-month progression-free survival (PFS-6). The trial was sized to be able to discriminate between a 15% and 35% rate for the GBM group alone and between a 20% and 40% rate for the entire cohort. There were 51 eligible patients, including 38 GBM and 13 AG patients, enrolled. The median age was 52 and 42 years, respectively. PFS-6 for the entire cohort was 17.6%. PFS-6 was 15.7% (95% confidence interval [CI], 0.07-0.31) for the GBM patients and 23% (95% CI, 0.07-0.52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353
Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C. H. M., Robey, R. W., Pommier, Y. G., Fojo, T., & Bates, S. E. (1999) · PubMed · Cited by 263
Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C. A. M., de Jong, L. A., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2001) · PubMed · Cited by 231
National Cancer Institute-Common Toxicity Criteria
下山正徳 (1999) · 癌と化学療法 · Cited by 222
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 162
Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna, R., Morton, C. L., Danks, M. K., & Potter, P. M. (2000) · PubMed · Cited by 158
Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., & Wienkers, L. C. (1997) · PubMed · Cited by 152
Cited by
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationKreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Self-citationBevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Metadata
- Authors
- Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., Nicholas, M. K., Schiff, D., Greenberg, H., Junck, L., Fink, K., Hess, K., & Kuhn, J.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-01
- Volume
- 8
- Issue
- 2
- Pages
- 189-193
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2099808007
- Cited by
- 254
- References
- 22
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. https://app.cochat.ai/papers/10.1215/15228517-2005-010
- The paper
- Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., Nicholas, M. K., Schiff, D., Greenberg, H., Junck, L., Fink, K., Hess, K., & Kuhn, J. (2006). A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. Neuro-Oncology. https://doi.org/10.1215/15228517-2005-010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.